Exclusive Remicade Contracts Are Slowing Biosimilar Uptake
Executive Summary
Exclusive contracts for J&J's Remicade have posed challenges for Pfizer's Inflectra in the commercial insurance market, the biosimilar's maker said during its second quarter earnings call.
You may also be interested in...
J&J’s Gorsky Hails Strong Performance By Immunology Therapies Tremfya, Stelara
A strong fourth quarter and full-year 2019 performance by J&J was driven by significant sales growth for Tremfya and Stelara. CFO Wolk said a $4bn opioids settlement remains on track.
Biocon Staying Firm On Insulins Path, Including Glargine
Biocon has reported strong second-quarter earnings and underscored its interest in the insulins space, including insulin glargine, at least for now. Merck & Co recently called off plans to commercialize its Lantus version.
Biocon Staying Firm On Insulins Path, Including Glargine
Biocon has reported strong second-quarter earnings and underscored its interest in the insulins space, including insulin glargine, at least for now. Merck & Co recently called off plans to commercialize its Lantus version.